Original Articles Open access

EFFICACY OF SODIUM HYPOCHLORITE IN THE DEGRADATION ANTINEOPLASTIC DRUGS BY NMR SPECTROSCOPY

Authors

Published
14 February 2025
Section
Original Articles
DOI
10.4081/gimle.447
Pages
109-120

Abstract

Antineoplastic drugs are used to treat cancer, having their therapeutic effect by inhibiting the cell division process. Although cancer cells, due to their rapid growth, are more sensitive to the toxic effects of chemotherapeutic agents, healthy cells and tissues may also be damaged. Many studies show acute and chronic toxicity both in patients treated with chemotherapy and in exposed workers. In fact, exposure to these substances can also be linked to the formation of different types of secondary tumors. The International Agency on Research on Cancer (IARC) included some antineplastic drugs in Group 1 (carcinogenic to humans), in Group 2A (probable carcinogens for In recent years, many studies have evidenced the presence of antineoplastic drug contamination on work surfaces, materials and floors and based on these observations, international and national guidelines have been published to limit occupational exposure, with particular attention to procedures post-preparation of chemotherapy to limit as much as possible the accumulation of contaminated residues.
The aim of the following study is to determine the effectiveness of the degradation of four antineoplastic drugs: 5-fluorouracil, azacitidine, cytarabine and irinotecan using a low concentration of sodium hypochlorite solution (0.115%). The analytical platform used to monitor the degradation course of the substances under examination was hydrogen nuclear magnetic spectroscopy (H NMR). In the same experimental conditions the effectiveness of the degradation of the same antineoplastic drugs with a 99.9% ethanol solution was also evaluated. The study showed that the best degradation efficiency (> 90% ) is obtained with the hypochlorite solution after 15 minutes.

Keywords

References

  1. 1) Agents classified by the TARC monographs, volumes 1-109. (http://monographs.iarc.fr/ ENG/Classification/ClassificationsAlphaOrder.pdf) 2) Falck K, Gröhn P, Sorsa M, et al. Mutagenicity in urine of nurses handling cytostatic drugs. Lancet 1979; 1: 1250-51. DOI: https://doi.org/10.1016/S0140-6736(79)91939-1
  2. 3) Cloak MM, Connor TH, Stevens KR, et al. Occupational exposure of nursing personnel to antineoplastic agents. Oncol Nurs Forum 1985; 12: 33-9.
  3. 4) Fishbein L. Perspectives on occupational exposure to antineoplastic drugs. Arch Geschwulstforsch 1987; 57: 219-48.
  4. 5) Gruppo di lavoro dell' Associazione Italiana di Medicina Preventiva dei Lavoratori della Sanità. Summary of recommendations for a rational implementation of the ministry of health guidelines on the prevention of occupational risks in handling antineoplastic agents. Med Lav 2001; 92: 137-48.
  5. 6) Center for disease control and prevention. NIOSH alert: preventing occupational exposure to antineoplastic and other hazardous drugs in health care settings. DHHS - NIOSH Publication Number 2004-165. 7) Petrelli G, Palmi S. Esposizione professionale a chemioterapici antiblastici: rischi per la riproduzione e strategie per la prevenzione. Roma: Istituto Superiore di Sanità; 2002 (Rapporti ISTISAN 02/16). 8) Lancharro PM, De Castro-Acuña Iglesias N, González-Barcala FJ, et al. Evidence of exposure to cytostatic drugs in healthcare staff: a review of recent literature. Farm Hosp 2016; 40: 604-21.
  6. 9) World Health Organization. Laboratory biosafety manual. 3ra ed. 2004, rev. 2014. (https://www.who.int/csi/resources/publications/ biosafety/Biosafety 7.pdt) 10) American Society of Heath-System Pharmacists - ASHP Guidelines on Handling Hazardous Agents. 2004. https://academic.oup.com/ajhp/article-abstract/75/24/1996/5248544?redirectedFrom=fulltext&login=false
  7. 11) I.S.P.E.S.L. Documento di Linee Guida per la Sicurezza e la salute dei lavoratori esposti a chemioterapici in ambiente ospedaliero. GU n. 236 del 7 ottobre 1999.
  8. 12) Perico A, Lorini C, Biliotti T, et al. Valutazione dell'esposizione professionale a chemioterapici antiblastici in ambiente ospedaliero in Toscana Ann Ig 2003; 15: 363-71.
  9. 13) Royal Free Hospital NHS Trust and Royal Free and University College Medical School of University College London (royal free campus). Spillage management arrangements and guidance. 2003. (https://www.scribd.com/document/107490302/Spillage-Management). 14) Gallo V, Intini N, Mastrorilli P, et al. Performance assessment in fingerprinting and multi component quantitative NMR analyses. Analytical Chemistry 2015; 87: 6709-17. DOI: https://doi.org/10.1021/acs.analchem.5b00919
  10. 15) Gödecke T. Napolitano JG, Rodríguez-Brasco MF, et al. Validation of a Generic Quantitative 'H NMR Method for Natural Products Analysis Phytochem Anal 2013; 24: 581-97. DOI: https://doi.org/10.1002/pca.2436
  11. 16) Cheenou H, Aaron P, Alonzo Justin Y. Vang et al. Real-Time Enzyme Kinetics by Quantitative NMR Spectroscopy and Determination of the Michaelis-Menten Constant Using the Lambert-W Function. J Chem Educ 2015; 92: 1943-8. DOI: https://doi.org/10.1021/acs.jchemed.5b00136
  12. 17) Maiwald M, Grützner T, Ströfer E, et al. Quantitative NMR spectroscopy of complex technical mixtures using a virtual reference: chemical equilibria and reaction kinetics of formaldehyde-water1,3,5-trioxane. Anal Bioanal Chem 2006; 385: 910-7. DOI: https://doi.org/10.1007/s00216-006-0477-3
  13. 18) Wishart DS, Jewison T, Guo AC, et al. HMDB 3.0 - The Human Metabolome Database in 2013. Nucleic Acids Res 2013; 41: D 801-7. 19) Sulkowska A, Bojko B, Równicka J, et al. Competition of cytarabine and aspirin in binding to serum albumin in multidrug therapy. Biopolymer. 2006; 81: 464-72. DOI: https://doi.org/10.1002/bip.20445
  14. 20) D'Amelio N, Aroulmoji V, Toraldo A, et al. Aggregation properties and structural studies of anticancer drug Irinotecan in DMSO solution based on NMR measurements. J Mol Str 2012; 1013: 26-35. 21) Schönberger T, Monakhov YB, Lachenmeier et al. Guide to NMR Method Development and Validation - Part 1: Identification and Quantification. Eurolab Technical Report number 01/2014. (www.eurolab.org). DOI: https://doi.org/10.1016/j.molstruc.2012.01.012
  15. 22) Negri S, Oddone E, Morandi F, et al. Validation of cleaning procedures used in an Italian Hospital Pharmacy for antineoplastic drug decontamination: a new tool for industrial hygiene. Med Lav 2019; 110(2): 93-101.
  16. 23) Sottani C, Grignani E, Oddone E, et al. Monitoring Surface Contamination by Antineoplastic Drugs in Italian Hospitals: Performance-Based Hygienic Guidance Values (HGVs) Project. Ann Work Expo Health. 2017;61(8):994-1002. DOI: https://doi.org/10.1093/annweh/wxx065
  17. 24) Kiffmeyer TK, Tuerk J, Hahn M et al. Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies - the MEWIP project. Ann Occup Hyg. 2013; 57: 444-55.
  18. 25) Connor TH, DeBord D G, Pretty J R et al. Evaluation of antineoplastic drug exposure of health care workers at three university-based Us cancer centers. J Occup Environ Med 2010; 52: 1019-27. DOI: https://doi.org/10.1097/JOM.0b013e3181f72b63

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.

PlumX Metrics

License

Copyright (c) 2025 The Author(s)

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.

Most read articles by the same author(s)